Literature DB >> 10221368

Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors.

M F Beauchesne1, S J Shalansky.   

Abstract

To determine the role of growth factors in nonchemotherapy drug-induced agranulocytosis, we reviewed 118 published reports of administration of colony-stimulating factors for the disorder. Main outcomes were total duration of neutropenia and mortality. The mean time to neutrophil recovery was 4.6 +/- 3.2 days and 7.7 +/- 5.1 days in patients with a granulocyte count at diagnosis of 0.1-0.5 x 10(3)/mm3 and less than 0.1 x 103/mm3, respectively. The mortality rate was 4.2%. Without therapy with growth factors, the mean time to neutrophil recovery after discontinuation of the offending agent was reported to be 10 +/- 8 days. The mortality rate was 16% in one study. We conclude that hematopoietic growth factors may shorten the duration of neutropenia and reduce mortality in patients with severe drug-induced agranulocytosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221368     DOI: 10.1592/phco.19.4.299.30941

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

1.  Hyperleucocytosis following G-CSF treatment for sulfasalazine-induced agranulocytosis.

Authors:  Kenneth Chan; Redwan Farooq
Journal:  BMJ Case Rep       Date:  2015-07-15

2.  [Clinical otorhinolaryngological symptoms of metamizole-induced agranulocytosis].

Authors:  T Send; S Westermann; K W G Eichhorn; M Jakob
Journal:  HNO       Date:  2015-03       Impact factor: 1.284

Review 3.  Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients.

Authors:  Emmanuel Andrès; Esther Noel; Jean-Emmanuel Kurtz; Nourredine Henoun Loukili; Georges Kaltenbach; Frédéric Maloisel
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases.

Authors:  Rachel Mourot-Cottet; Frédéric Maloisel; François Séverac; Olivier Keller; Thomas Vogel; Martine Tebacher; Jean-Christophe Weber; Georges Kaltenbach; Jacques-Eric Gottenberg; Bernard Goichot; Jean Sibilia; Anne-Sophie Korganow; Raoul Herbrecht; Emmanuel Andrès
Journal:  Drugs Real World Outcomes       Date:  2016-12

5.  History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs.

Authors:  Emmanuel Andrès; Rachel Mourot-Cottet; Frédéric Maloisel; Olivier Keller; Thomas Vogel; François Séverac; Martine Tebacher; Jacques-Eric Gottenberg; Jean-Christophe Weber; Georges Kaltenbach; Bernard Goichot; Jean Sibilia; Anne-Sophie Korganow; Raoul Herbrecht
Journal:  J Clin Med       Date:  2017-09-26       Impact factor: 4.241

Review 6.  State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies.

Authors:  Emmanuel Andrès; Noel Lorenzo Villalba; Abrar-Ahmad Zulfiqar; Khalid Serraj; Rachel Mourot-Cottet; And Jacques-Eric Gottenberg
Journal:  J Clin Med       Date:  2019-09-01       Impact factor: 4.241

7.  GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent.

Authors:  Annegret Winkler; Silke Kietz; Hagen Bahlmann; Gunel Jafarzade; Holger N Lode; Matthias Heckmann
Journal:  Clin Case Rep       Date:  2016-07-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.